December 18, 2025

Top 10 States to Practice Pulmonology

The following list highlights the states that offer the most favorable conditions for pulmonologists.

Conexiant

December 17, 2025

Lung Cancer Screening Follow-up Shows Gaps

Investigators highlight disparities in diagnostic follow-up intensity after abnormal lung cancer screening findings across Lung Imaging Reporting and Data System categories using a national analysis of registry-linked Medicare data.

Conexiant

December 09, 2025

Ironically, Smoking May Have Saved My Life

I was diagnosed with stage IV non-small cell lung (NSCLC) adenocarcinoma on August 1, 2013—World Lung Cancer Day. If it hadn’t been for an article that caught my eye the year before about the recommen...

The ASCO Post

December 09, 2025

Christine M. Lovly, MD, PhD, FASCO, Named Head, Thoracic Oncology, at City of Hope

Christine M. Lovly, MD, PhD, FASCO, an expert on lung cancer with almost 2 decades of experience in clinical care, translational research, and academic leadership, will spearhead the new national thor...

The ASCO Post

December 09, 2025

Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved sevabertinib, an oral targeted therapy, for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (ERBB2) mut...

The ASCO Post

November 20, 2025

Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer

The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.

Dana-Farber

November 30, 2025

Robotic Bronchoscopic Cryobiopsy Improves Diagnostic Yield Without Compromising Safety

Traditional guided bronchoscopy isn't good at reaching certain small lesions and some areas of the lung. As a result, diagnostic yields—the proportion of biopsies that result in a specific diagnosis—tended to hover around 60-70 percent. Now, a Mount Sinai researcher says that adding a cryoprobe helps achieve a definitive diagnosis in 90-95 percent of cases.

Mount Sinai New York

August 09, 2023

Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial

As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit wit...

The ASCO Post

September 21, 2023

NeoCOAST: Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC

An anti–PD-L1 monoclonal antibody in combination with other immuno-oncology agents may outperform treatment with the agent on its own in the neoadjuvant setting for patients with early-stage non–small...

The ASCO Post